StockTipsArenaBeta

BUY Aurobindo Pharma — Arun Kumar Mantri

BUYAurobindo Pharma
Aurobindo Pharma share price target & all analyst calls

byArun Kumar MantriHorizon: BTST28 Aug 2026, 3:14 pm ISTvia CNBC Awaaz.

Entry₹1,645.3Inferred
Target₹1,692
Total upside +2.84% (call closed)
Stop loss₹1,640-0.32% risk
Exit₹1,64031 Aug 2026, 9:33 am
Stop-loss hit-0.32%
Follow Arun Kumar Mantri for new calls(17% target hit, 102 closed calls)Get alertsWatch AUROPHARMA for new buy/sell callsGet alertsSee 3 active BTST picks this session

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 31 Aug 2026
3 supporting2 neutral2 opposing
Supports the BUY call (3)

2 advisors have active swing BUY calls on this stock, all issued in the last 14 days

Advisor consensus · adjacent horizon·31 Aug · today

Aurobindo Pharma Share Price Gains As USFDA Concludes Inspection At Subsidiary Lannett's Unit

NewsNdtv-Profit·24 Aug · 6d ago

(opens in new tab)

Aurobindo Pharma US FDA inspection ends with one observation at AuroPeptides facility

NewsCnbc-Tv18·21 Aug · 1w ago

(opens in new tab)
Neutral / worth noting (2)

Aurobindo Pharma’s API plant gets three US FDA observations after inspection

NewsCnbc-Tv18·28 Aug · 2d ago

(opens in new tab)

Here's why these four pharma stocks are in focus today

NewsCnbc-Tv18·24 Aug · 1w ago

(opens in new tab)
Weighs against the BUY call (2)

USFDA Issues Three Observations To Aurobindo Pharma Arm's Facility In Andhra

NewsNdtv-Profit·28 Aug · 2d ago

(opens in new tab)

Aurobindo Pharma US subsidiary Lannett Company LLC faces 4 observations from the USFDA

NewsLivemint·24 Aug · 6d ago

(opens in new tab)

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Aurobindo Pharma

All analyst calls on Aurobindo Pharma

More from Arun Kumar Mantri

Every call and its outcome